文献速递胰腺与胆道疾病消化内镜

直肠吲哚美辛联合十二指肠乳头喷洒肾上腺素增加内镜逆行胰胆管造影术后胰腺炎风险

Rectal Indomethacin and Spraying of Duodenal Papilla With Epinephrine Increases Risk of Pancreatitis Following Endoscopic Retrograde Cholangiopancreatography.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-10-31

一项在中国10个中心进行的双盲随机试验,纳入1158例原生乳头行ERCP患者,比较直肠吲哚美辛联合乳头喷洒肾上腺素(IE组,n=576)与联合喷洒生理盐水(IS组,n=582)预防术后胰腺炎的效果。因安全性和无效性提前终止,IE组PEP发生率8.5%高于IS组5.3%(RR 1.60,95%CI 1.03-2.47,P=0.033)。结论认为不应将肾上腺素喷洒与直肠吲哚美辛联用于预防PEP。

要点

  • IE组PEP发生率8.5% vs IS组5.3%(RR 1.60,95%CI 1.03-2.47,P=0.033)。
  • 两组乳头括约肌切开后出血(IE组2.1% vs IS组1.5%)和胆道感染(IE组1.2% vs IS组2.2%)无显著差异。
  • 研究因安全性和无效性在中期分析时提前终止。

核心结论

  • 与单用直肠吲哚美辛相比,联合乳头喷洒肾上腺素增加PEP风险(IE组8.5% vs IS组5.3%,RR 1.60,95%CI 1.03-2.47,P=0.033)。
  • 作者认为不应将肾上腺素喷洒与直肠吲哚美辛联用于预防PEP。

研究设计与样本

  • 在中国10个中心进行的双盲随机对照试验,时间为2017年2月至2017年10月。
  • 纳入1158例原生乳头行ERCP的患者,随机分为IE组(n=576)和IS组(n=582)。
  • 所有患者在ERCP前30分钟内接受单剂直肠吲哚美辛;ERCP结束时向十二指肠乳头喷洒20 mL稀释肾上腺素(IE组)或生理盐水(IS组)。
  • 主要结局为总体PEP发生率,按意向性治疗原则分析。

主要发现

  • 研究因安全性和无效性在中期分析时提前终止,两组基线特征相似。
  • IE组49例(8.5%)发生PEP,IS组31例(5.3%)发生PEP(RR 1.60,95%CI 1.03-2.47,P=0.033)。
  • 乳头括约肌切开后出血发生率IE组2.1% vs IS组1.5%,两组无显著差异。
  • 胆道感染发生率IE组1.2% vs IS组2.2%,两组无显著差异。

临床怎么用

  • 作者认为不应将肾上腺素喷洒与直肠吲哚美辛联用于预防PEP。

局限性

  • 研究因安全性和无效性在中期分析时提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Rectal indomethacin and spraying of the duodenal papilla with epinephrine might reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). We performed a randomized trial to compare the effects of the combination of indomethacin and epinephrine (IE) vs indomethacin plus saline (IS) in prophylaxis of post-ERCP pancreatitis (PEP). METHODS: We performed a double-blind trial at 10 centers in China, from February 2017 to October 2017, of 1158 patients with native papilla undergoing ERCP. The patients were assigned randomly to groups given IE (n = 576) or IS (n = 582). All patients received a single dose of rectal indomethacin within 30 minutes before ERCP; 20 mL of dilute epinephrine (IE group) or saline (IS group) then was sprayed on the duodenal papilla at the end of ERCP. The primary outcome was the incidence of overall PEP. Data were analyzed on an intention-to-treat principle. RESULTS: The study was terminated at the interim analysis for safety concerns and futility. The groups had similar baseline characteristics. PEP developed in 49 patients in the IE group (8.5%) and in 31 patients in the IS group (5.3%) (relative risk, 1.60, 95% CI, 1.03-2.47; P = .033). There were no significant differences between groups in proportions of patients with postsphincterotomy bleeding (2.1% in the IE group and 1.5% in the IS group) and biliary infection (1.2% in the IE group and 2.2% in the IS group). CONCLUSIONS: In a randomized trial, we found the combination of rectal indomethacin with papillary epinephrine spraying increased the risk of PEP compared with indomethacin alone. Spray epinephrine should not be used with rectal indomethacin for prevention of post-ERCP pancreatitis. ClincialTrials.gov no: NCT03057769.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Luo H, Wang X, Zhang R, et al. Rectal Indomethacin and Spraying of Duodenal Papilla With Epinephrine Increases Risk of Pancreatitis Following Endoscopic Retrograde Cholangiopancreatography. Clin Gastroenterol Hepatol. 2018. PMID: 30391434. doi:10.1016/j.cgh.2018.10.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。